Clinical Trials Logo

Interstitial Lung Disease clinical trials

View clinical trials related to Interstitial Lung Disease.

Filter by:

NCT ID: NCT05514522 Recruiting - Clinical trials for SARS-CoV-2 Infection

The UK Interstitial Lung Disease Long-COVID19 Study (UKILD-Long COVID): Understanding the Burden of Interstitial Lung Disease in Long COVID.

UKILD
Start date: August 18, 2021
Phase:
Study type: Observational

Prospective observational study of hospitalised and non-hospitalised patients post- infection with SARS-CoV-2. The study aims to recruit 2000 individuals, with proven COVID-19, who were not hospitalised but presented to Long-COVID clinics with persistent respiratory symptoms such as breathlessness or cough and are referred for cross-sectional imaging (computer tomography, CT) at baseline (3 months weeks after their first COVID-19 symptoms). The study will run for 18 months.

NCT ID: NCT05505409 Recruiting - Clinical trials for Interstitial Lung Disease

Efficacy and Safety of Pirfenidone in CTD-ILD

Start date: June 22, 2022
Phase: Phase 4
Study type: Interventional

A single-center randomized controlled study will be used to observe the efficacy and safety of pirfenidone on CTD-ILD patients for 24 months. The main research endpoints is the lung function (FVC) at 6 months. The clinical dyspnea score, 6-minute walking distance, index of lung function and imaging indicators are evaluated, as well as primary disease activity and adverse reactions of therapy with glucocorticoid and immunosuppressants up to 24 months.

NCT ID: NCT05482607 Recruiting - Systemic Sclerosis Clinical Trials

Evaluation of HRCT Patterns in Systemic Sclerosis-associated Interstitial Lung Disease

LUNGSCLEROCT
Start date: January 1, 2023
Phase:
Study type: Observational

Systemic sclerosis (SSc) is a heterogeneous systemic autoimmune disease with distinct prognosis according to patients. Interstitial lung disease (ILD) concerns almost 50 % of SSc patients and represents the main cause of mortality. SSc-ILD is variable: from limited forms (with asymptomatic patients) to extensive lesions. Disease course in SSc-ILD is also highly variable: patients can experience stable disease, slow or fast progression. Investigators performed unsupervised clustering analysis to classify SSc-ILD according to elementary radiological lesions on HRCT scan.

NCT ID: NCT05450276 Enrolling by invitation - Clinical trials for Interstitial Lung Disease

Patient-Reported Outcome Study of Project ECHO for ILD

Start date: July 2022
Phase:
Study type: Observational

The study will assess whether patients of providers participating in Project ECHO for ILD experience reduced stress, including financial stress, based on their ability to receive timely and local care and services, The study will employ nested mixed-method design at baseline, at 6 months and at 12 months to answer the study question.

NCT ID: NCT05445817 Recruiting - Clinical trials for Interstitial Lung Disease

Pulmonary Care and Research Collaborative Patient Registry

Start date: July 2022
Phase:
Study type: Observational [Patient Registry]

The purpose of this research study is to build and maintain a registry of people with interstitial lung disease (ILD). Medical information collected for this registry may be used to advance ILD and pulmonary research and improve patient care. This is an observational registry. Participants will not receive any investigational treatments or investigational drugs as part of their participation in this registry.

NCT ID: NCT05417776 Recruiting - Clinical trials for Interstitial Lung Disease

Collagen-targeted PET Imaging for Early Interstitial Lung Disease

Start date: September 28, 2022
Phase: Phase 2
Study type: Interventional

The goal of this study is to investigate the ability of [68Ga]CBP8 to detect collagen deposition in early interstitial lung disease.

NCT ID: NCT05392881 Recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

Interstitial Lung Disease Research Unit Biobank

ILDRU
Start date: August 9, 2021
Phase:
Study type: Observational [Patient Registry]

Establish a interstitial lung disease (ILD) registry and biorepository to lead towards a further understanding of the disease.

NCT ID: NCT05391100 Recruiting - Clinical trials for Rheumatoid Arthritis

Screening of Patients With Rheumatoid Arthritis for Interstitial Lung Disease

Start date: February 1, 2022
Phase:
Study type: Observational

The quantitative and qualitative analysis of RA lung involvement in the Hungarian population

NCT ID: NCT05382572 Recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

Pulmonary Fibrosis Foundation Community Registry

Start date: July 11, 2022
Phase:
Study type: Observational [Patient Registry]

Pulmonary fibrosis (PF) results from a diverse group of health conditions and affects the lives of patients (including those who are post lung transplant), caregivers and family members. The Pulmonary Fibrosis Foundation Community Registry will offer an online portal where participants can self-enroll and directly contribute information about their experience with PF to be compiled into a longitudinal data set for use by researchers.

NCT ID: NCT05375435 Recruiting - Clinical trials for Interstitial Lung Disease

Efficacy and Safety of Triple Therapy in Patients With Anti-MDA5 Antibody-positive Dermatomyositis

Start date: January 1, 2022
Phase: Phase 4
Study type: Interventional

We conduct this study to investigate the efficacy of triple therapy (high-dose glucocorticoids + cyclophosphamide + calcineurin inhibitor) compared with dual-therapy regimens (high-dose glucocorticoids + cyclophosphamide/calcineurin inhibitor) and whether it reduces the risk of poor pulmonary prognosis in patients with moderate to high risk anti-MDA5+ DM.